Glanbia FY25 revenue rises 2.3% on volume growth
Company sees 7% to 11% EPS growth in 2026
26 February 2026
1 minute read
By: Ireland’s Glanbia reported preliminary FY25 revenue up 2.3% year-over-year to $3.95 billion, driven by volume growth across all segments, reported Reuters.
Adjusted earnings per share declined 3.4% year-over-year to $1.35. Net income totalled $283.90 million.
The company said record whey input costs negatively affected Performance Nutrition EBITDA margin. It reported volume growth across all segments, with strong demand in the Health & Nutrition and Dairy Nutrition divisions boosting revenue.
Glanbia announced a €100 million share buyback authorization for 2026.
For 2026, the company expects adjusted EPS growth of 7% to 11% on a constant currency basis. It anticipates operating cash conversion of 85%+ in FY 2026 and plans capital expenditure of $100 million to $110 million.
The current average analyst rating on the shares is “buy,” with nine “strong buy” or “buy” recommendations and one “hold.” There are no “sell” or “strong sell” ratings. Wall Street’s median 12-month price target for Glanbia PLC is €18.00, about 9% above its Feb. 24 closing price of €16.52.
The stock recently traded at 14 times the next 12-month earnings, compared with a P/E of 12 three months ago.
